Oxotremorine
![]()  | |
| Clinical data | |
|---|---|
| Pregnancy category  | 
  | 
| Routes of administration  | Oral, intravenous | 
| ATC code | 
  | 
| Legal status | |
| Legal status | 
  | 
| Identifiers | |
IUPAC name 
  | |
| CAS Number | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.000.662 | 
| Chemical and physical data | |
| Formula | C12H18N2O | 
| Molar mass | 206.289 g·mol−1 | 
| 3D model (JSmol) | |
SMILES 
  | |
InChI 
  | |
|   | |
Oxotremorine is a drug that acts as a selective muscarinic acetylcholine receptor agonist.[1]
Oxotremorine produces ataxia, tremor and spasticity, similar to those symptoms seen in Parkinsonism, and has thus become a research tool in experimental studies aimed at determining more effective anti-Parkinsonian drugs.[2]
Oxotremorine also produces antipsychotic effects.[3]
References
- ↑ Tang C, Castoldi AF, Costa LG (April 1993). "Effects of the muscarinic agonist oxotremorine on membrane fluidity in rat lymphocytes". Biochemistry and Molecular Biology International. 29 (6): 1047–54. PMID 8330013. INIST 4025194.
 - ↑ Craig CR, Stitzel RE, eds. (2004). Modern Pharmacology with Clinical Applications. Lippincott Williams & Wilkins. ISBN 978-0-7817-3762-3.
 - ↑ Maehara S, Hikichi H, Satow A, Okuda S, Ohta H (November 2008). "Antipsychotic property of a muscarinic receptor agonist in animal models for schizophrenia". Pharmacology, Biochemistry, and Behavior. 91 (1): 140–9. doi:10.1016/j.pbb.2008.06.023. PMID 18651995. S2CID 12225821. INIST 20678587.
 
See also
    This article is issued from Wmcloud. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.
